Evaluation of polygenic risk score for risk prediction of gastric cancer

Table 1 Main characteristics of the included studies

Ref.	Population	Design	Group	Sample size	Sex, (%)	Age, (%)	SNPs (RA, OR)
Mao et al[19], 2017	Chinese	Case-control	GC, HC	2631, 4373	Male: 5100 (72.8%); female: 1904 (27.2%)	< 60 yr 3299 (52.9%); ≥ 60 yr 3705 (47.1%)	rs1514175 (A, 1.01), rs2815752 (A, 1.07), rs574367 (T, 1.11), rs12463617 (C, 1.05), rs1861411 (A, 1.02), rs6545814 (G, 1.05), rs10513801 (T, 1.17), rs2535633 (G, 0.98), rs16858082 (T, 0.96), rs261967 (C, 1.02), rs888789 (A, 0.99), rs6890814 (C, 0.99), rs4713766 (A, 1.05), rs9356744 (T, 1.03), rs9473924 (T, 0.98), rs17150703 (G, 1), rs4735692 (A, 1.02), rs11142387 (C, 1.06), rs1211166 (A, 1.02), rs11191580 (C, 0.92), rs10160804 (A, 0.99), rs11030104 (A, 1.02), rs11604680 (G, 0.97), rs2237892 (T, 1), rs671 (G, 1.12), rs897057 (C, 1.04), rs7989336 (A, 1.03), rs9568867 (A, 1.03), rs4776970 (A, 1.05), rs1558902 (A, 1.04), rs2531995 (T, 1.05), rs4788102 (A, 1.08), rs7503807 (A, 1), rs9299 (T, 0.9), rs591166 (A, 1.08), rs11671664 (G, 0.97), rs3810291 (A, 1.02)
Choi et al[20], 2020	European	Cohort	GC	272 cases in 400807 individuals	Male: 186372 (46.5%); female: 214435 (53.5%)	NR	rs2990223 (G, 1.27), rs10036575 (T, 1.23), rs2294008 (T, 1.21)
Jin et al[21], 2020	Chinese	Cohort	GC	Training set: 10254 cases and 10914 controls; validation set: 692 cases in 100220 individuals	Training set: NR; validation set: Male: 42862 (42.8%); female: 57358 (57.2%)	Training set: NR; validation set: < 60 yr 69805 (69.7%); ≥ 60 yr 30415 (30.3%); mean in case: 60.82 ± 9.33; mean in controls: 53.64 ± 11.00	NR
Qiu et al[22], 2020	Chinese	Case-control	GC, HC	1115, 1172	Male: 1615 (70.6%); female: 672 (29.4%)	< 60 yr 1162 (50.8%); ≥ 60 yr 1125 (49.2%)	rs13361707 (C, 1.47), rs2294008 (T, 1.19), rs4072037 (T, 1.38), rs3762272 (T, 1.21), rs2274223 (G, 1.35), rs80142782 (T, 1.36)
Wang et al[23], 2020	Chinese	Case-control	GC, HC	2631, 4373	Male: 5100 (72.8%); female: 1904 (27.2%)	< 60 yr 3299 (52.9%); ≥ 60 yr 3705 (47.1%)	rs1801133 (A, 1.02), rs2275565 (G, 1.01), rs4660306 (T, 1), rs1047891 (A, 1), rs9369898 (A, 1), rs548987 (C, 0.98), rs42648 (G, 1.01), rs1801222 (A, 0.99), rs12780845 (A, 1.01), rs7130284 (C, 1.01), rs2251468 (C, 1.03), rs154657 (A, 1.01), rs12921383 (C, 1.01), rs838133 (A, 1.02), rs234709 (C, 0.99)
Duan et al[24], 2021	Chinese	Case-control	GC, HC	544, 544	Male: 825 (75.8%); female: 263 (24.2%)	Mean in case: 57.80 ± 12.06; mean in controls: 57.02 ± 11.97	rs1859168 (C, 1.09), rs3815254 (A, 0.98), rs4784659 (C, 0.55), rs579501 (A, 0.71), rs77628730 (A, 1.26), rs6989575 (C, 1.03), rs7816475 (A, 1.19), rs6470502 (T, 0.51), rs1518338 (C, 1.08), rs2867837 (G, 0.95), rs12494960 (A, 2.62), rs74798803 (T, 0.97), rs7818137 (T, 1.2), rs550894 (T, 1.13), rs3825071 (A, 1.48), rs580933 (G, 0.98), rs7943779 (A, 1.54), rs911157 (T, 1.74), rs16981280 (C, 0.76), rs2273534 (C, 0.92), rs957313 (T, 1.04)
Ishikura et al[25], 2021	Japanese	Case-control	GC, HC	Training set: 696 cases and 1392 controls; validation set: 795 cases and 795 controls	Training set: Male: 1560 (74.7%); female: 528 (25.3%); validation set: Male: 1180 (74.2%); female: 410 (25.8%)	Training set: < 60 yr 1034 (49.5%); ≥ 60 yr 1054 (50.5%); validation set: < 60 yr 621 (39.1%); ≥ 60 yr 969 (60.9%)	rs4072037 (G, 1.35), rs2294008 (T, 0.62), rs7849280 (G, 0.24)
Park et al[26], 2021	Korean	Case-control	GC, HC	450, 1136	Male: 836 (52.7%); female: 750 (47.3%)	Mean in case: 55.4 ± 10.7; mean in control: 52.1 ± 8.5	rs2294008 (T, 1.2), rs6656150 (C, 0.8), rs8280142782 (C, 0.6), rs760077 (A, 0.8), rs140081212 (A, 0.8), rs4460629 (T, 0.8)

SNP: Single nucleotide polymorphism included in studies; GC: Gastric cancer group; HC: Healthy controls; NR: Not reported/Not retrieved; RA: Allele associated with gastric cancer; OR: Odds ratio.